Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.

Detaylı Bibliyografya
Asıl Yazarlar:	Edwards, S, Emmas, C, Campbell, H
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2005

Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
Yazar:: Edwards, S, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients
Yazar:: Xi You, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence
Yazar:: Pasquale Sansone, ve diğerleri
Baskı/Yayın Bilgisi: (2024-05-01)

Retrospective evaluation of piperacillin–tazobactam, imipenem–cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia
Yazar:: Eman Youssif, ve diğerleri
Baskı/Yayın Bilgisi: (2018-07-01)

In vitro study of the embolic characteristics of imipenem/cilastatin particles
Yazar:: Hiroki Nakamura, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
Yazar:: Maria Agudelo, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

Randomized Comparison of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Patients with Intra-abdominal Infection
Yazar:: Alex A. Erasmo
Baskı/Yayın Bilgisi: (2004-07-01)

Corrigendum to “Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients” [Journal of Global Antimicrobial Resistance 36 (2024) 252-259]
Yazar:: Xi You, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
Yazar:: Ryan K. Shields, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
Yazar:: Takahiro Arima, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
Yazar:: Mona I. Shaaban, ve diğerleri
Baskı/Yayın Bilgisi: (2017-04-01)

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
Yazar:: Paul Laffont-Lozes, ve diğerleri
Baskı/Yayın Bilgisi: (2024-10-01)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
Yazar:: Jaesh Naik, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

A Prospective Randomized Trial of Imipenem-Cilastatin Versus Clindamycin/Tobramycin in the Treatmentof Intra-Abdominal and Pelvic Infections
Yazar:: Lionel A Mandell, ve diğerleri
Baskı/Yayın Bilgisi: (1993-01-01)

Imipenem/cilastatin encapsulation in UIO-66-NH2 carrier as a new strategy for combating imipenem-resistant Pseudomonas aeruginosa isolates
Yazar:: Shakila Baei Lashaki, ve diğerleri
Baskı/Yayın Bilgisi: (2025-05-01)

Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin
Yazar:: Chang-Hua Chen, ve diğerleri

Increased antibiofilm and growth inhibitory effect of Imipenem/Cilastatin nanoliposomes against clinical Pseudomonas aeruginosa isolates
Yazar:: Faezeh Milani, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

Transcatheter arterial embolization using imipenem/cilastatin sodium and microspheres for traumatic pseudoaneurysm: A case report
Yazar:: Takaki Hirano, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
Yazar:: Xiaokui Huo, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01)

CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT
Yazar:: I. I. Shteynberg, ve diğerleri
Baskı/Yayın Bilgisi: (2015-03-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplantation
Yazar:: C Kani, ve diğerleri
Baskı/Yayın Bilgisi: (2005-06-01)

Successful treatment of multiple microbleeds in a large area of the small bowel by transcatheter arterial embolization using imipenem/cilastatin as embolization material
Yazar:: Sakiko Hiraki, MD, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa
Yazar:: Glenn J. Rapsinski, ve diğerleri
Baskı/Yayın Bilgisi: (2025-03-01)

Decrease in the effectiveness of valproic acid against the background of antibacterial therapy with imipenem/cilastatin in pediatric practice: A case report
Yazar:: A. B. Strok, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Validated Reverse Phase HPLC Method for the Determination of DEHP Content in Reconstituting Diluents and in Reconstituted Solutions of Imipenem and Cilastatin for Injection
Yazar:: A. K. Chaudhary, ve diğerleri
Baskı/Yayın Bilgisi: (2010-01-01)

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in <i>Pseudomonas aeruginosa</i> Isolates from Sepsis
Yazar:: Telma de Sousa, ve diğerleri
Baskı/Yayın Bilgisi: (2023-11-01)

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: a single-center retrospective study
Yazar:: Sakiko Hiraki, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplan¬tation
Yazar:: Kani C., ve diğerleri
Baskı/Yayın Bilgisi: (2005-07-01)

Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii
Yazar:: E. Dahdouh, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database
Yazar:: Peng Jia, ve diğerleri
Baskı/Yayın Bilgisi: (2025-02-01)

Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
Yazar:: Qingxin Yang, ve diğerleri
Baskı/Yayın Bilgisi: (2023-12-01)

Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects
Yazar:: George G Zhanel, ve diğerleri
Baskı/Yayın Bilgisi: (1998-01-01)

Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in Pseudomonas aeruginosa
Yazar:: Hassuna NA, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China
Yazar:: Chen Y, ve diğerleri
Baskı/Yayın Bilgisi: (2018-11-01)

In vitro activity of meropenem, imipenem, cefepime, cefoxitin and ciprofloxacin against multiresistant Klebsiella pneumoniae.
Yazar:: P Pruekprasert, ve diğerleri
Baskı/Yayın Bilgisi: (2006-06-01)

Systematic review and meta-analysis of colistin plus meropenem therapy for the treatment of nosocomial pneumonia
Yazar:: Hazhir Moradi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-12-01)

A novel analytical method to assess the effect of imipenem/cilastatin on liver function laboratory indexes in Chinese underage inpatients: Probability distribution curve.
Yazar:: Le Zou, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
Yazar:: Rémy A. Bonnin, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
Yazar:: Özlem AYDEMİR, ve diğerleri
Baskı/Yayın Bilgisi: (2023-09-01)

Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience
Yazar:: Cristiana Leanza, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.

Benzer Materyaller

Benzer Materyaller